The FY18 AIMM Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on Grants.gov in August 2018.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to the Program Announcement is contingent on the availability of Federal funds.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) Research and Development Directorate (J9) manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

http://cdmrp.army.mil/pubs/press/2018/18dmrdp-aimmpreann

AIMM Research Award

• Independent investigators at all academic levels (or equivalent)
• Supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine
• Supports novel research concepts and development of enabling technologies; not intended to support incremental advances on previous or ongoing work
• Supports applied research efforts that initiate or enhance potential game-changers; clinical trials are not allowed.

·         Projects proposed should be relevant to at least one DoD medical research program area.  Cross-cutting research projects with the potential to benefit multiple DoD medical research program areas are highly encouraged. 

·         Applications using synthetic or systems biology-based approaches are highly encouraged

• ·         Preliminary data that are relevant to the proposed research are encouraged, but not required.

• Preproposal is required; application submission is by invitation only

·         Maximum funding of $350,000 for direct costs (plus indirect costs)

• Maximum period of performance is 18 months

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcement is released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY18 Defense Appropriations Act provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

 

FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

 

The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.  Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

·         Develop treatments that improve outcomes for men with lethal prostate cancer

·         Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

·         Define the biology of lethal prostate cancer to reduce death

·         Improve the quality of life for survivors of prostate cancer

 

http://cdmrp.army.mil/funding/pcrp

 

Health Disparity Research Award – Letter of Intent due September 20, 2018

• Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent)
• Or New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

·         Have the freedom to pursue individual aims without formal mentorship

·         Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award

• Have completed at least 3 years of postdoctoral training or fellowship and are within 10 years after completion of a terminal degree (excluding residency or family medical leave)

·         Supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 

·         Research ideas should be innovative, but primary emphasis will be placed on the potential impact of the proposed work.

·         Preliminary data are encouraged, but not required.

• Proposed projects may include basic, translational, or clinical research, including clinical trials.
• Must address at least one of the FY18 PCRP Overarching Challenges.
• New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.

·         Established Investigators:

·         Maximum funding of $1,000,000 for direct costs (plus indirect costs).

·         New Investigators:

·         Maximum funding of $600,000 for direct costs (plus indirect costs).

• Maximum period of performance is 3 years.

 

 

Health Disparity Scholar Award – Letter of Intent due bu September 20, 2018

By March 31, 2019

Postdoctoral Ph.D. or M.D. PIs:

• Must have successfully defended a doctoral thesis or possess an M.D. degree
• Have 3 years or less of postdoctoral research experience

·         Supports research opportunities focused on reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality for individuals in the early stages of their careers.

• PIs must have a designated mentor who is an experienced prostate cancer researcher.
• Must address at least one of the FY18 PCRP Overarching Challenges.

·         Maximum funding of $200K for direct costs (plus indirect costs).

• Maximum period of performance is 2 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website.

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

FY18 PRORP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The mission of the PRORP is to address the most significant gaps in care for the leading burden of injury for facilitating return-to-duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat and combat-related activities. 

Prolonged Field Care (PFC) has been identified as the number one capability gap across the Army.  PFC includes field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care.  In order to address this gap and prepare the orthopaedic field for the next conflict or mass event, the FY18 PRORP has identified several orthopaedic areas of focus for funding that will support patient care closer to the point of injury and to allow patients to more quickly return to duty/work. 

The PRORP will solicit research applications that specifically address at least one of the following FY18 Focus Areas:

• o   Animal Models - Develop animal models that replicate Prolonged Field Care-related injuries, including ischemia reperfusion injury and compartment syndrome.
• o   Device Development - Develop offloading and stability devices (e.g., braces, casting) for ligamentous injuries, small extremity fractures, and /or other non-severe common battlefield musculoskeletal injuries for immediate return to duty.
• o   Wound Infection – Evaluate and /or translate promising available clinical interventions in prevention and control of combat extremity wound infections (e.g., for long bone open fractures) to improve their durability to treat Service member injuries as close as possible to the point of injury.  Projects that further develop novel wound protectants for this population will also be considered.
• o   Treatment Techniques and Outcomes - Develop and /or evaluate optimal non-surgical and /or surgical treatment strategies and intervention delivery parameters (e.g., frequency, intensity, time, and intervention type) to rapidly remediate duty-limiting  impairments, functional limitations, or barriers to full duty readiness following orthopedic injuries.  Interventions may include, but are not limited to:  combination therapies (simultaneous application of multiple treatment modalities), injections, dry needling, manual therapy, therapeutic exercise, or other techniques to return Service members to duty within 72 hours.
• o   Surgical Care - Translate early research findings, in any of the below Surgical Care Areas, to humans.
• §  Surgical Care Areas: Peripheral Nerve Injuries, Prevention of Heterotopic Ossification, Volumetric Muscle Loss, Extremity Fractures, Pelvic Ring Injuries, Compartment Syndrome, Gaps in Clinical Practice Guidelines (http://www.usaisr.amedd.army.mil/cpgs.html), Surgical Techniques to Optimize Gait, Soft Tissue Trauma, Osteoarthritis
• o   Surgical Techniques and Outcomes - Evaluate optimal surgical treatment strategies, tools, and delivery parameters to improve functional outcomes of Service members who have sustained orthopaedic injuries.  The proposed research should address at least one topic from the Surgical Care Areas (listed below), and strategies to return the patient to duty and potentially shorten recovery in theater.
• §  Surgical Care Areas: Peripheral Nerve Injuries, Prevention of Heterotopic Ossification, Volumetric Muscle Loss, Extremity Fractures, Pelvic Ring Injuries, Compartment Syndrome, Gaps in Clinical Practice Guidelines (http://www.usaisr.amedd.army.mil/cpgs.html), Surgical Techniques to Optimize Gait, Soft Tissue Trauma, Osteoarthritis
• o   Rehabilitation Techniques and Outcomes – Evaluate optimal rehabilitation treatment strategies, tools, and delivery parameters to improve functional outcomes for immediate return to duty of Service members who have sustained orthopaedic injuries. 
• o   Acute Pain - Evaluate promising available or emerging clinical interventions to control acute pain (e.g., analgesics, anti-inflammatory agents, nerve blocks) following orthopaedic injuries in the pre-hospital setting.  Projects that investigate a pathway to enhance non-physician capabilities to deliver rapid, long lasting, analgesia with minimal cognitive side effects in an austere environment are encouraged.
• o   Improved Surgical Interventions - Develop or optimize orthopaedic surgical interventions to support their use in the pre-hospital environment.
• o   Tissue Regeneration:
• §  Development and preclinical testing of therapies for volumetric muscle loss due to traumatically damaged tissues of the extremities. 
• §  Develop and /or evaluate regenerative medicine therapies (devices, drugs, biologics, and /or techniques) for traumatically injured tissues of the extremities.
• §  Evaluate advanced regenerative medicine therapeutics for restoration of traumatically injured extremity tissues.

The following FY18 PRORP award mechanisms are released (note that Focus Area requirements vary by award mechanism):

http://cdmrp.army.mil/funding/prorp

Applied Research Award – Preproposal due July 30, 2018

• Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
• Pre-application is required; full application submission is by invitation only.
• Supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or combat-related activities.
• Proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.
• Clinical trials are not allowed under this award mechanism.
• Applications must address one the following FY18 PRORP Focus Areas:
• • Animal Models
  • Device Development
  • Wound Infection
  • Tissue Regeneration
• Maximum funding of $750,000 for total costs.
• Maximum period of performance is 3 years.

Clinical Trial Award – Preproposal due July 30, 2018

• Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
• Pre-application is required; full application submission is by invitation only.
• Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates.
• Funding must support a clinical trial and may not be used for preclinical research studies.
• Collaboration with military researchers and clinicians is encouraged.
• Studies that include active duty military or Veteran participants as all or a portion of the study population will be considered.
• Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
• Applications must address one the following FY18 PRORP Focus Areas:
• • Surgical Techniques and Outcomes
  • Rehabilitation Techniques and Outcomes
  • Acute Pain
  • Improved Surgical Interventions
  • Tissue Regeneration
• Maximum funding of $3 million (M) for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

Clinical Translational Research Award – Preproposal due July 30, 2018

• ·        Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
• ·        Pre-application is required; full application submission is by invitation only.
• ·        Supports high-impact and/or emerging research that may or may not be ready for a full scale randomized controlled clinical trial.
• ·        Funding must support clinical research studies involving humans.
• ·        Preliminary or published data relevant to the proposed research project are required.
• ·        Collaboration with military researchers and clinicians is encouraged.
• ·        Studies that include active duty military or Veteran participants as all or a portion of the study population will be considered.
• ·       Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
• ·        Applications must address one the following FY18 PRORP Focus Areas:

·        Maximum funding of $2M for direct costs (plus indirect costs),

·        Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY18 Defense Appropriation provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 OPORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov. 

OPORP awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  The intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the Orthotics and Prosthetics Outcomes research community in one or more of the FY18 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY18 Focus Areas:

• Orthotic or Prosthetic Device Form:  Understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
• Orthotic or Prosthetic Device Fit:  Understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
• Orthotic or Prosthetic Device Function:  Understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

http://cdmrp.army.mil/funding/oporp

 

Clinical Research Award – Preproposal due August 6, 2018

• Independent investigators at all academic levels (or equivalent)
• Supports research that evaluates the comparative effectiveness of orthotic and/or prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans with limb loss and/or limb impairment.
• Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
• Collaboration among academia, industry, the DoD, and the Department of Veterans Affairs (VA) is highly encouraged, including longitudinal outcomes studies.
• Applications submitted to the FY18 OPORP CRA must address one or more of the FY18 OPORP Focus Areas.
• Animal studies are not allowed.
• Clinical trials are not allowed.
• Preproposal submission is required; application submission is by invitation only.

·         Funding Level 1:

o   Maximum funding of $350,000 for total costs (direct costs plus indirect costs)

o   Maximum period of performance is 2 years.

·         Funding Level 2:

o   Maximum funding of $1,500,000 for total costs (direct costs plus indirect costs)

 

Clinical Trial Award – Preproposal due August 6, 2018

Independent investigators at all academic levels (or equivalent)

·         Supports rapid implementation of clinical trials with the potential to make significant impacts on improving health and well-being of Service members and Veterans with limb loss and/or limb deficit.

·         Supports research that evaluates the comparative effectiveness of orthotic and/or prosthetic clinical interventions using patient-centric outcomes.

·         Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.

·         Collaboration among academia, industry, the DoD, and the VA is highly encouraged, including longitudinal outcomes studies.

·         Applications submitted to the FY18 OPORP CTA must address one or more of the FY18 OPORP Focus Areas.

·         Preclinical research is not allowed.

·         Preproposal submission is required; application submission is by invitation only.

• Preclinical research is not allowed.

·         Funding Level 1:

o   Maximum funding of $350,000 for total costs (direct costs plus indirect costs)

o   Maximum period of performance is 2 years.

·         Funding Level 2:

o   Maximum funding of $2,500,000 for total costs (direct costs plus indirect costs)

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY18 Defense Appropriation provides $5 million (M) to the Department of Defense Lupus Research Program (LRP) to support innovative and impactful research that addresses fundamental issues in lupus.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 LRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY18 LRP must address at least one of the three Focus Areas listed below:

•           Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus disease over time, strategies and technologies to subtype patients, lupus disease mechanisms, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, socioeconomic studies, environmental studies, and epidemiological studies.

•           Understand how the underlying genetic components and gene environment interactions of lupus disease relate to clinical disease characteristics using functional genomic studies.

•           Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genomics of lupus disease in particular tissues, and metabolomics and how understanding the underlying pathobiology will improve quality of life of patients.

http://cdmrp.army.mil/funding/lrp

 

Concept Award – Letter of Intent due October 10, 2018

Investigators at all academic levels

·         Supports highly innovative, untested, potentially groundbreaking concepts in lupus research

·         Emphasis is on innovation

·         Clinical trials are not allowed

• Preliminary data is not required

·         Maximum funding of $150,000 for total costs

• Maximum period of performance is 1 year

 

Impact Award – Letter of Intent due October 10, 2018

Investigators at or above Assistant Professor (or equivalent)

·         Supports innovative, high-risk/high-reward research

·         Emphasis is on impact

·         Clinical trials are not allowed

• Preliminary data is encouraged but not required

·         Maximum funding of $525,000 for total costs

• Maximum period of performance is 3 years

 

A pre-application (Letter of Intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY18 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Epilepsy Research Program (ERP) to explore the causative links between traumatic brain injury (TBI) and epilepsy, with the hope that, one day, post-traumatic epilepsy (PTE) will be preventable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

 

FY18 ERP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

 

Applications should also address at least one of the ERP FY18 Focus Areas.  An application that proposes research outside of the FY18 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

 

The ERP FY18 Focus Areas are as follows:

 

Epidemiology:  Epidemiological characterization of PTE following TBI, which may include:

• Risk factors such as demographics, genetic factors, organic head injury factors, or type of insult
• Differentiation of PTE and Psychogenic Non-Epileptic Seizures (PNES)
• Outcomes including latency to epilepsy, morbidities and comorbidities, and mortality
• Pre-existing conditions including psychological and psychiatric risk factors
• Treatment

Markers and Mechanisms:  Identifying markers or mechanisms (via clinical prospective or preclinical models) that address PTE, which may include the following:

• ·         Early detection

• Diagnosis
• Prognosis
• Morbidity
• Comorbidity
• Mortality
• Risk stratification

 

Note:  Research considering the development of new models or better characterization of existing etiologically relevant models for PTE, including repetitive TBI, could be considered under this Focus Area.

 

Longitudinal Studies:  Studies of the natural evolution of PTE, which may include the following:

• Seizure frequency and severity
• Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
• Latency between injury and PTE
• Mortality
• Treatment
• Quality of life of individuals with PTE

 

http://cdmrp.army.mil/funding/erp

 

Longitudinal Risk Factors Award – Preproposal due July 26, 2018

The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).  Investigators must have a patient cohort identified.

Intent:  To facilitate high-impact, systematic, cohort-based research investigating the natural evolution of PTE from TBI.

·         Responsive to the Longitudinal Focus Area Only.

·         Preliminary data are required.

·         Must describe how the inter-relationship between TBI and PTE will be assessed or characterized.

·         Must describe the nature of the cohort (military, etc.)

·         Must describe the study outcomes to be captured.

·         Must describe the nature of the TBIs within the study cohort.

·         Requires a Biostatistician.

·         Applications that develop interdisciplinary teams or consortia as part of the support plan for executing the research are encouraged.

• ·         Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

• Maximum funding of $2,500,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

• ·         Indirect costs may be proposed in accordance with the institution's rate agreement.

 

 

Idea Development Award –Letter of Intent due September 20, 2018

Level I:  The Principal Investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent).  

Level II:  The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Intent:  To solicit research to understand the magnitude and underlying mechanisms of PTE, especially in Service members and Veterans, while also benefitting the civilian community. 

·       Level I is intended to support high-risk or high-gain research from researchers at or above the level of a post-doctoral fellow (or equivalent). 

·       Level II is intended to support a more mature, hypothesis-driven research project.

The following Focus Areas are open to both Levels I and II:

·         Epidemiology

·         Markers and Mechanisms

·         Longitudinal Studies

·         Preliminary data, while not required, are encouraged for both levels.

Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

Level I:

·       Maximum funding of $300,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 2 years.

·       Indirect costs may be proposed in accordance with the institution's rate agreement.

Level II:

·       Maximum funding of $500,000 for direct costs (plus indirect costs).

·       Maximum period of performance is 3 years.

Indirect costs may be proposed in accordance with the institution's rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

 

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support the United States Medical Research Acquisition Activity.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

http://cdmrp.army.mil/funding/kcrp

 

Concept Award – Letter of Intent due July 11, 2018

Investigators at all academic levels.

·       Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

·       Emphasis on innovation.

·       Funding for clinical trials is not allowed.

·       Preliminary data are not allowed.

·       Blinded review

·      Maximum funding of $75,000 for direct costs (plus indirect costs).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Maximum period of performance is 1 year.

 

Idea Development Award – Letter of Intent due September 5, 2018

Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

Early Career Investigators:

Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

·       Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

·       Preliminary data are required.

·       Innovation and Impact are the most important review criteria.

·       Clinical trials are not allowed.

·       FY18 KCRP Areas of Emphasis are strongly encouraged.

·       Maximum funding of $400,000 in direct costs (plus indirect costs).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Period of performance is not to exceed 2 years.

 

Physicians Research Award – Letter of Intent due September 5, 2018

The PI must be a physician with clinical duties and/or responsibilities who, at the application submission deadline, is within 3 years of having initiated his/her first appointment as an Instructor, Assistant Professor, or equivalent

·       Supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research.

·       This award emphasizes equally the quality of the proposed research project and the career development of the Principal Investigator (PI), which should prepare physicians for careers in basic, population science, translational, or clinical kidney cancer research.

·       Clinical trials are not allowed.

·       Preliminary data are not required.

·       Maximum funding of $200,000 in direct costs (plus indirect costs).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Period of performance is not to exceed 2 years.

 

Technology Development Award – Letter of Intent due September 5, 2018

Investigators at or above the level of Assistant Professor (or equivalent) are eligible.

Applicants with limited kidney cancer experience are strongly encouraged to collaborate with those having substantial expertise in kidney cancer research and/or kidney cancer model systems.

·       Supports emerging technologies to aid clinical and patient outcomes.

·       Product-driven award intended to advance the development of technologies to aid clinical and patient outcomes, including prevention, detection, diagnosis, treatment, or quality of life.

·       Transition plan is required.

·       Clinical trials are not allowed.

·       Preliminary data are required (need not be in kidney cancer).

·       Maximum funding of $300,000 in direct costs (plus indirect costs).

·       Period of performance is not to exceed 3 years.

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Translational Research Partnership – Letter of Intent due September 5, 2018

The Initiating PI must be at or above the level of Assistant Professor (or equivalent).

The Partnering PI must be at or above the level of Assistant Professor or equivalent.  Postdoctoral fellows are not eligible to be Partnering PI’s.

·       Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

·       Supports translational correlative studies.

·       Preliminary data are required.

·       Clinical trials are not allowed.

·       Maximum funding of $600,000 for direct costs (plus indirect costs).

·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Maximum period of performance is 3 years.

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY18 Defense Appropriation provides $12 million (M) to the Department of Defense Reconstructive Transplant Research Program (RTRP) to support research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The RTRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 RTRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government.

Focus Areas:  The FY18 RTRP encourages research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA) in the following focus areas:

• ·        Reduce the risks of VCA-associated immunotherapy
• ·        Revolutionize ex vivo VCA tissue preservation strategies to extend the timeline between procurement and transplantation
• ·        Identify near- and long-term functional, quality-of-life, and psychosocial outcomes in VCA

http://cdmrp.army.mil/pubs/press/2018/18rtrppreann

Concept Award (CA)

Investigators at or above the level of postdoctoral fellow (or equivalent)

• Pre-application (Letter of Intent) is required.
• Supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplant. 
• Preliminary data are NOT allowed.
• Reviewers at both tiers of review will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organizations.
• Applications must address at least one of the FY18 RTRP Focus Areas.

·      Maximum funding of $200,000 for total costs (direct plus indirect costs)

• ·      Maximum period of performance is 18 months

 

Investigator-Initiated Research Award (IIRA)

Independent investigators at all academic levels (or equivalent)

• Preproposal is required; full application submission is by invitation only.
• Supports studies with potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.
• Preliminary or published data required.
• Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.
• Applications must address at least one of the FY18 RTRP Focus Areas.

Individual PIs:

·      Maximum funding of $1 million (M) for total costs

·      Maximum period of performance is 3 years

Multiple PI Option:

·      Maximum funding of $1.5M for total costs

• ·      Maximum period of performance is 3 years

 

Qualitative Research Award (QRA)

Independent investigators at all academic levels (or equivalent)

• Preproposal is required; full application submission is by invitation only.
• Supports qualitative research studies that will help researchers and clinicians to better understand the experiences of individuals who are considering, or have already received, reconstructive transplant surgery.
• Demonstrated qualitative research experience within the research team is required.
• Applications must address the following FY18 RTRP Focus Area:

○       Identify near- and long-term functional, quality-of-life, and psychosocial outcomes in VCA

Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.

·      Maximum funding of $1M for total costs

·      Maximum period of performance is 3 years

 

Multiple PI Option:

·      Maximum funding of $1.5M for total costs

• ·      Maximum period of performance is 3 years.

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY18 Defense Appropriations Act provides $10 million (M) to the Department of Defense Hearing Restoration Research Program (HRRP) to support innovative, high-impact hearing restoration research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY18 HRRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

The mission of the HRRP is to advance the science of hearing restoration by delivering groundbreaking research and solutions that remove barriers to the successful treatment of auditory system injury. Applications submitted to the FY18 HRRP must addresses one or more of the following Focus Areas (revised for FY18):

• Develop reliable in vitro human models for evaluating hearing restoration therapies.
• Accelerate translation of biological regeneration mechanisms into therapies that restore auditory function.
• Develop and or validate techniques/methods to assess and or treat auditory dysfunction as related to synaptopathy, hidden hearing loss, and central auditory processing disorders.

http://cdmrp.army.mil/funding/hrrp

Translational Research Award (TRA) – Preproposal due July 17, 2018

• Independent investigators at all academic levels (or equivalent)
• Preproposal is required; application submission is by invitation only.
• Supports animal and human studies to:
• develop reliable in vitro human models for evaluating hearing restoration therapies, or
• Accelerate translation of biological regeneration into therapies that restore auditory function, including, for example, synaptic plasticity and hair cell and neural regeneration.
• Preliminary data required.
• Clinical trials are not allowed.
• Maximum funding of $1M for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

Focused Research Award (FRA) – Preproposal due July 17, 2018

• Independent investigators at all academic levels (or equivalent)
• Preproposal is required; application submission is by invitation only.
• Supports animal and human studies to develop and/or validate techniques and/or methods to assess and/or treat auditory dysfunction as related to synaptopathy, hidden hearing loss, and central auditory processing disorders. Examples include:
• • field tool(s) to diagnose hidden hearing loss and to inform operational readiness;
  • batteries of differential diagnostics tests that pinpoint the location(s) of auditory damage;
  • treatments for the various types of damage that result in the loss of hearing leading to decreased operational readiness.
• Preliminary data required.
• Clinical trials are not allowed.
• Maximum funding of $1M for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Extramural applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the HRRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk 
301-682-5507 
help@eBrap.org

The FY18 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical PH- and TBI-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).  The CDMRP provides PH/TBIRP execution management support for DHP core research program areas, including the Joint Program Committee 6/ Combat Casualty Care Research Program (JPC-6/CCCRP).  JPC-6/CCCRP provides strategic oversight for the PH/TBI funds associated with this funding Program Announcement.  The Defense Health Agency is working in collaboration with the U.S. Department of Veterans Affairs (VA) and other Federal agencies on research efforts to improve the lives of Service members and Veterans affected by traumatic brain injury, posttraumatic stress disorder, and other mental health conditions.

The PH/TBIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  The FY18 PH/TBIRP Program Announcement and General Application Instructions for the following award mechanism is anticipated to be posted on the Grants.gov website in July 2018.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the Government.

http://cdmrp.army.mil/pubs/press/2018/18phtbipreann_limbic

FY18 PHTBIRP Joint DoD and VA Long-term Impact of Military-relevant Brain Injury Consortium (LIMBIC)

• Independent investigators at all academic levels (or equivalent)
• Preproposal is required; application submission is by invitation only.
• The objective of this funding opportunity is to support a single consortium to study a large cohort of TBI subjects to include Service members and Veterans.

Required Focus Areas (each must be addressed in application)

• Identification of differences in long-term neurological outcomes from blast-related vs. impact only TBI.
• Identification of pathophysiological and biomarker signatures that may be predictive of long-term outcomes and healthcare utilization.
• Analysis of existing biorepositories and/or biospecimens from a longitudinal cohort to identify novel biomarkers for chronic TBI.
• Stratification and characterization of TBI subgroups based on recovery and neurodegeneration.
• Analysis of existing DoD and VA TBI databases for correlations and associations of TBI comorbidities.

Secondary Focus Areas (in no particular order)

• Understanding the economic burden of TBI. 
• Identification of potential differences between single vs. multiple TBI history on outcomes.
• Identification of potential differences in long-term neurological outcomes from blast-related vs. impact-only TBI.
• Identification of potential differences between individuals with exposure to repetitive low-level blast and those without.
• Identification and investigation of neurodegeneration and TBI-associated comorbidities.
• Evaluation of chronic mTBI biomarker profile(s) over time and injury severity.
• Identification of potential variations in long-term outcomes in deployment-related vs nondeployment-related TBI.
• Determination of whether a history of TBI is associated with lower performance metrics.
• Maximum allowable costs (direct and indirect) are $25M via the DoD.
• Up to an additional $5M per year for 5 years will be provided by the VA to VA sites, depending on availability of funds.
• • To be eligible for VA funding at a specific research site, a participating investigator must have a VA-paid appointment of at least five-eighths at the time of pre-application submission, unless a previous eligibility waiver has been granted.
• Maximum period of performance is 5 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil